Materials and Methods
We used an aca with computer II (Du Pont, aca Division,
Wilmington,
DE 19898) and a Model 250 spectrophotometer (Gilford Instrument Laboratories, Inc., Oberlin, OH 44074).
Reagents
Aqueous bilirubin, 0.5 gIL. Dissolve 12.5 mg of bilirubin (Standard Reference Material no. 916; National Bureau of Standards, Gaithersburg, MD) in 1 mL of dimethyl sulfoxide in a 25-mL volumetric flask. Add 2 mL of aqueous Na2CO3 (0.1 molJL) and 18 mL of a 70 g/L solution of human serum albumin (Fraction V, cat. no. A2386; Sigma Chemical Co., St. Louis, MO 63178). Neutralize the solution (pH 7.0) by adding 2 mL of 0.1 molIL HC1 and dilute to volume with the human serum albumin solution. A bilirubin blank solution is prepared by the same procedure, but omitting the bilirubin.
Controls. To estimate precision, we used two control sera 
Procedure
Aliquots of fresh patients' serum that were received in the laboratory for routine analysis were used in this study. Icteric, hemolyzed, and lipemic sera were excluded. Paired aliquots of serum samples were analyzed simultaneously by both aca and Dow methods. All HDLC measurements were made in duplicate. The day-to-day precision for the aca and Dow HDLC methods was estimated by analyzing, in duplicate, three control sera during a period of three months (n = 22). The within-day precision for the aca method was estimated by 20 replicate determinations with the same three control sera.
Other Studies
Effect of hemoglobin. A blood sample from an apparently healthyambulatory individual was collected into two tubes (10 mL each). We prepared hemolyzed serum from the blood in one tube, by a freeze-thaw cycle. The separated hemolyzed serum was assayed for hemoglobin; the nonhemolyzed serum separated from the second tube was assayed for HDLC.
Serum samples with final hemoglobin concentrations ranging from 1 to 10 g/L were prepared by mixing the hemolyzed and nonhemolyzed sera. The samples were assayed for HDLC and the results expressed as the percentage recovered (nonhemolyzed serum HDLC = 100%). All measurements were made in duplicate.
Effect of bilirubin. A nonicteric serum pool (total bilirubin 5 mg/L) was mixed with aqueous bilirubin to obtain samples with final bilirubin concentrations ranging from 10 to 250 mg/L. A corresponding blank sample was prepared by mixing the serum pool with blank bilirubin. All samples were assayed for HDLC and total bilirubin. The percent recovery of HDLC from icteric samples was calculated by using the HDLC value of each corresponding blank as 100%. All measurements were made in duplicate. A smaller Mr dextran sulfate incompletely precipitated VLDL and LDL cholesterol, whereas a larger size precipitated some HDLC. Given these findings, the Dow HDLC method (dextran sulfate, Mr 150 000) would be expected to underestimate HDLC.
To assess the correlation between the aca and the hepariniMn2 methods, we analyzed three CDC serum pools having HDLC reference values determined by heparin/Mn precipitation method and by the CDC reference cholesterol method (modified Abell-Kendall procedure) (6). The differences between the reference and the mean measured HDLC concentrations in the three sera were 0.013, 0.035, and 0.034 g/L, respectively, with corresponding analytical recoveries of 104.9%, 110.0%, and 106.7%. Therefore, in comparison with the heparinIMn2 method, the aca method overestimates HDLC.
The day-to-day precision for the aca and Dow HDLC methods was essentially the same ( Table 1 ). The within-day CV was less than 3% for three different control materials. The day-to-day precision for the aca method includes two calibrations of the instrument and therefore is substantially greater than the within-day precision.
In evaluating the interference by bilirubin, hemoglobin, and lipemia with the aca HDLC method, we found that bilirubin concentrations up to 170 mg/L and hemoglobin concentrations up to 4.3 g/L did not significantly alter the result for HDLC in serum. Lipemic specimens with triglyceride concentrations up to 5.43 g/L had clear supernates after treatment with the phosphotungstate precipitating reagent; the HDLC recovered from these supernates was between 98.5% and 106.9%. Lipemic specimens containing a triglyceride concentration greater than 5.43 g/L showed a broad p band on lipoprotein electrophoresis, indicating incomplete precipitation of the LDL and VLDL fractions. Thus, lipemic specimens with a triglyceride concentration greater than 5.4 g/L should not be assayed for HDLC with the aca method. 
Materials and Methods

Apparatus
We used Technicon-recommended methodologies and reagents. For one part of the study, we modified one of our two scs by adding a five-turn mixing coil (part no. 178-G196-01) before and after the pre-dilution cartridge, to assess the effect of additional mixing on precision.
To measure viscosity (five determinations with each specimen) we used a size-75 routine viscometer (no. CFRC; Cannon-Fenske, State College, PA 16801), kept in a constant-temperature water bath at 37 #{176}C. 
Control Sera
Decision level 3 (lot no. C012234, compared with Ortho abnormal in Table 1 ) was shipped by the manufacturer on solid C02-which had sublimed by the time the shipment was received, although the product was still cold to the touch. The product was immediately stored at -20 #{176}C. The manufacturer, queried about the warming of the product, indicated that no damage had occurred and that the product was suitable for use. A second lot of Decision level 3 (lot no. C104033, compared with Omega H in Table 1 ) was obtained with solid CO2 still present in the shipping container and immediately stored at -20 #{176}C. The Decision level 3 was packaged in 20-mL plastic squeeze bottles, which were stored at -20 #{176}C until used in this study, at which point it was kept in a refrigerator at 2 to 8 #{176}C, for no longer than six days.
The two lyophilized control sera studied were Ortho abnormal (lot no. 10T564; Ortho Diagnostic Systems, Inc., Raritan, NJ 08869) and Omega II (lot no. 4822F001B; Hyland Laboratories, Malvern, PA 19355), reconstituted with the diluent supplied by the manufacturers, and according to their instructions.
Procedures
Each control sera was analyzed five times per day for 20 (Decision vs Ortho) or 16 (Decision vs Omega) working days. The control sera were placed in consecutive cups in alternating order for analysis by SMAC.
The effect of carryover and additional mixing on the precision of Decision level 3 was also evaluated. For carryover, Decision level 3 was placed in two consecutive cups and analyzed five times per day for 15 working days. To assessthe effect of additional mixing, one of our two SMAC instruments was modified by adding two five-turn mixing coils and Decision level 3 was analyzed five times per day for 15 working days on both SMAC instruments.
Total imprecision was assessed by calculating the variance and coefficient of variation (CV) for each analyte among the three control materials. The p value for the F ratio (variance for Decision divided by the variance for the lyophilized control material) was obtained by use of pro-
